Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Want to cut your energy bills? Here’s how five experts are doing it 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
JERSEY, Channel Islands, May 31, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017 at 3:00 p.m. Eastern Time at the Grand Hyatt New York.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
